This website uses cookies

Read our Privacy policy and Terms of use for more information.

This story has all the ingredients to go viral on X, and it already has. A wealthy tech entrepreneur just announced an extremely shiny new object: a full-body ultrasound, available at a spa in San Francisco. Elon Musk reposted it, and boom, hundreds of physicians piled on to point out the myriad problems that would inevitably follow if this thing hit the mass market.

The main issue? It's an argument we've heard before, through every wave of new technology. We heard it when wearables were in the headlines, as various forms of AI arrived in healthcare, with new tech-driven primary care practices, with whole-body MRI scans, and with diagnostic technologies like liquid biopsies. It's the fear that technologies claiming to detect disease early will instead produce thousands of "incidentalomas." Healthy, wealthy patients flood the system demanding tests and procedures they don't need, adding cost, increasing anxieties, and introducing new health risks.

Reserve Your Spot for Upcoming Webinars!

My reaction?

Perhaps I've become cynical, but my first thought was simply: let them try.

The system has so many institutionalized barriers that this is going to take an act of God to succeed. Even if the tech works exactly as advertised, it'll only reach a small patient population that can afford to pay cash. Insurance reimbursement would require clinical studies, years of market education, long sales cycles, and more. Good luck getting through all of that. Liquid biopsy companies, which screen for cancer, are still fighting sweeping coverage denials 15 years in, despite plenty of evidence showing efficacy as an alternative to tissue-based biopsy.

So the system will probably kill this company after a few years, especially if it can’t find a way to make a profit off of it. It's the fate of countless innovators.

On the incidentaloma question, I remain sympathetic. More data doesn't necessarily make us any healthier, and there's real literature here worth taking seriously. A review in Radiologic Clinics of North America lays out how incidentally detected findings carry substantial downstream costs, inclusive of cascades of follow-up tests, procedures, and patient worry, while noting that the true long-term, societal cost of all that has barely been quantified. The skeptics aren't wrong that we don't fully understand what we're unleashing. 

That said, in the rush to a hot take, we gloss over some of the benefits this kind of wellness and prevention-focused technology can provide.

logo

Want more? Second Opinion Premium goes further.

Second Opinion Premium membership gives you even more depth, with exclusive reporting, member-only insights, and practical tools you can put to work.

Upgrade to Premium

Premium membership unlocks:

  • Exclusive deep dives and strategic perspectives
  • Market maps, guides, and frameworks
  • Members-only webinars and events
  • Exclusive reports and evidence-backed analysis

Reply

Avatar

or to participate

Keep Reading